Good MorningEquity markets rebounded on Thursday on hopes that inflation was subsisting but these hopes are likely misplaced. Today's PCE price index will tell the tale, and it is expected to confirm the acceleration of monthly inflation and that inflation is still running well above the Fed's 2.0% target. The S&P 500 action is also telling; Thursday's market closed with a gain but the candle formed is dark and consistent with consolidation within a bear market. Price action is still below the 30-day EMA, a sign that short-term traders are bearish on the market.
Next week could be another down week for the market. There is not much on the economic calendar, but a raft of earnings reports is due out from the retail sector. So far, the results are better than expected but point to slowing and contraction in 2023. More news of this variety will harm what are already declining estimates for the 2nd half of the year and add additional downward pressure to the S&P 500. Featured: The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Legacy Research) 
|
Stocks | | | Shares in Asia were mixed Friday after Wall Street broke its longest losing streak since December with a modest rally led by tech stocks.
Benchmarks rose in Tokyo and Sydney but fell in Hong Kong, Shanghai and Seoul. Oil prices rose while U.S. futures edged lower.
Japa... Read the Full Story |
|
From Our PartnersThere's a tiny biotech in Cambridge that's using breakthrough technology to treat blindness.
This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return. | | Get the Details Here >>> |
|
Stocks | | |
Bitcoin is screaming higher, up roughly 45% on the year, making its first convincing rally since last summer and holding above the critical psychological $20,000 level. The wildly bullish, one-sided price action comes at an interesting time. The crypto industry is in "crypto winter" right now, lik... Read the Full Story |
|
Markets | | |
If Garmin (NYSE: GRMN) has anything to its credit, and it has quite a lot, it has diversification. This technology powerhouse makes and markets a wide range of gadgets and components used by governments, businesses and individuals in use cases that span all verticals. If one segment sees weakness,... Read the Full Story |
|
From Our PartnersThe news wants to scream “doom and gloom” about the current market. Conditions feel uncertain – that’s the prevailing sentiment. But guess what? There’s NEVER any real certainty in the market. Reveal how you can take advantage of this current market.
(**By clicking link you are subscribing to The Investor Newsletter Daily Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
| | The #1 Strategy For Uncertain Market Conditions |
|
Markets | | | Consumer prices in Japan jumped in January by the most in more than 41 years, the government reported Friday, adding to pressure on the central bank to adjust its longstanding ultra-lax monetary policy.
The key price indicator, which excludes volatile fresh foods, rose 4.2% last mont... Read the Full Story |
|
Markets | | | Beyond Meat on Thursday reported better-than-expected fourth quarter sales despite flagging consumer demand and lower prices.
The plant-based meat maker said its revenue fell 21% to $80 million in the October-December period. Still, that beat Wall Street's expectations. Analysts polle... Read the Full Story |
|
From Our PartnersA strange event (that no one has warned you of) is about to disrupt the foundations of the U.S. political, economic, and financial system… and could cause devastating losses for unprepared investors | | Go here for all the details |
|
Markets | | | The founder of the troubled digital start-up Ozy Media pleaded not guilty Thursday to federal fraud charges accusing him of scheming to prop up his financially struggling company, which hemorrhaged millions of dollars before it shut down amid revelations of possibly deceptive business practices.
... Read the Full Story |
|
Tech | | | A lowcredit score can hurt your ability to take out a loan, secure a good interest rate, or increase the spending limit on your credit card.
Some reasons for a low score are out of your control — such as unexpected medical debt or a lack of credit history.
Credit rati... Read the Full Story |
|
Markets | | |
If you are wondering if the rally in the TJX Companies (NYSE: TJX) is over the answer is probably not. The bigger question is what will happen between now and the following new high, and that is a consolidation. The company’s Q4 results and outlook for 2023 support the current price action a... Read the Full Story |
|
Markets | | |
Alibaba Group (NYSE: BABA) rose in pre-market trading in New York; its shares increased by more than 6%. The online retailer considerably surpassed the average expectation of 35 billion yuan by reporting net profits of 46.8 billion yuan ($6.8 billion). Just above expectations, revenue increased 2.... Read the Full Story |
|
Markets | | |
Shares of NVIDIA (NASDAQ: NVDA) are rocketing higher after some surprisingly good news. The company reported better-than-expected Q4 results led by AI and gaming. The recovery in gaming is a real surprise because all signs from within the industry are that slowing is the theme of 2023.
This means... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. | | View Today's Stock Pick |
|
